Caldera Therapeutics Launches with $112.5M in Total Capital
Why It Matters
The sizable raise accelerates development of a novel bispecific therapy that could reshape treatment options for inflammatory bowel disease and related immune disorders, attracting both patients and investors.
Caldera Therapeutics Launches with $112.5M in Total Capital
By FinSMEs · January 14, 2026
Caldera Therapeutics, Inc., a Cambridge, MA‑based clinical‑stage biotechnology company, launched with $112.5 M total capital raised.
The amount consisted of a $75 M Series A round from Atlas Venture, LAV and venBio, and most recently a $37.5 M Series A‑1 round led by Omega Funds, with participation from new investors Wellington Management and Janus Henderson Investors.
The company intends to use the funds to expand operations and its R&D efforts.
Led by CEO Praveen Tipirneni, Caldera Therapeutics is developing CLD‑423, a first‑in‑class bispecific antibody targeting the clinically validated IL‑23p19 and TL1A pathways for the treatment of inflammatory bowel disease (IBD) and other immunologic and inflammatory diseases.
The company also announced that the first subjects have been dosed in a Phase 1 healthy‑volunteer trial of CLD‑423, the same bispecific antibody targeting IL‑23p19 and TL1A.
FinSMEs
14/01/2026
Comments
Want to join the conversation?
Loading comments...